

The Psychology of Neurofeedback: Clinical Intervention Even if Applied Placebo

Robert T. Thibault

McGill University and Chapman University

Amir Raz

McGill University; The Lady Davis Institute for Medical Research, Montreal, Quebec, Canada; and Chapman University

Advocates of neurofeedback make bold claims concerning brain regulation, treatment of disorders, and mental health. Decades of research and thousands of peer-reviewed publications support neurofeedback using electroencephalography (EEG-nf); yet, few experiments isolate the act of receiving feedback from a specific brain signal as a necessary precursor to obtain the purported benefits. Moreover, while psychosocial parameters including participant motivation and expectation, rather than neurobiological substrates, seem to fuel clinical improvement across a wide range of disorders, for-profit clinics continue to sprout across North America and Europe. Here, we highlight the tenuous evidence supporting EEG-nf and sketch out the weaknesses of this approach. We challenge classic arguments often articulated by proponents of EEG-nf and underscore how psychologists and mental health professionals stand to benefit from studying the ubiquitous placebo influences that likely drive these treatment outcomes.

Keywords: self-regulation, psychosocial influences, neurofeedback, EEG, placebo

Whereas a large corpus of studies suggests that neurofeedback using electroencephalography (EEG-nf)—the original and most widely practiced form of neurofeedback—constitutes an effective clinical intervention, applying this technique remains controversial, expensive, and time-consuming. In EEG-nf, participants aim to self-regulate an ongoing feedback signal derived from electrical brain activity related to a specified behavior. As EEG-nf remains the only neurofeedback technique available to patients, we restrict our discussion to this putative treatment and forego discussing research surrounding functional MRI (fMRI)-neurofeedback (see Thibault, Lifshitz, & Raz, 2016, for a survey of emerging neurofeedback modalities).

First employed to treat attention-deficit/hyperactivity disorder (ADHD) and epilepsy, some practitioners now leverage EEG-nf to rehabilitate motor skills, boost creativity, maximize cognitive performance, and treat a range of clinical disorders including depression, alcoholism, autism spectrum disorder, and insomnia. Discussion of the mechanisms subserving these supposed effects, however, remains

mostly absent from published accounts (Zuberer, Brandeis, & Drechsler, 2015). Meanwhile, proponents of neurofeedback continue to tacitly attribute its alleged benefits to the cutting-edge process of receiving and modulating real-time neural data while often fallaciously presuming that subspectrums of electrical brain oscillations directly control single behaviors.

Does Neurofeedback Work?

Intriguingly, EEG-nf appears to benefit participants regardless of the feedback source (Thibault, Lifshitz, Birbaumer, & Raz, 2015); sham neurofeedback—derived from an unrelated signal—treats clinical conditions as does veritable neurofeedback (Arnold et al., 2013; Esmail & Linden, 2014; Lansbergen, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2011; Lofthouse, Arnold, Hersch, Hurt, & DeBeus, 2012; Logeman, Lansbergen, van Os, Bocker, & Kenemans, 2010; Perreau-Linck, Lessard, Lévesque, & Beauregard, 2010; Sonuga-Barke et al., 2013; Van Dongen-Boomsma, Vollebregt, Slaats-Willemse, & Buitelaar, 2013; Vollebregt, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2014; Vollebregt, van Dongen-Boomsma, Slaats-Willemse, & Buitelaar, 2014). Thus, placebo factors permeate EEG-nf and likely account for the majority of relevant experimental findings and clinical outcomes (Thibault & Raz, 2016b).

This state-of-affairs calls for a complementary research agenda aiming to better understand psychosocial factors and exploit such phenomena in a cost-effective and transparent

Robert T. Thibault, Integrated Program in Neuroscience, McGill University, and Institute for Interdisciplinary Behavioral and Brain Sciences, Chapman University; Amir Raz, Departments of Psychiatry, Psychology, and Neurology & Neurosurgery, McGill University; The Lady Davis Institute for Medical Research, Montreal, Quebec, Canada; and Institute for Interdisciplinary Behavioral and Brain Sciences, Chapman University.

Correspondence concerning this article should be addressed to Amir Raz, 4333 Cote Ste. Catherine, Montreal, QC, H3T 1E4, Canada. E-mail: amir.raz@mcgill.ca



Robert T. Thibault

manner. Here, we briefly overview relevant highlights from this research domain, point out the tenuous findings in support of EEG-nf, the specious logic that often prevails, and the conflicts of interest that abound. After arguing that EEG-nf may help certain symptoms—although through alternative mechanisms than those people commonly

consider—we conclude with a few suggestions about how to enhance and maximize these clinical benefits.

The Scarce Evidence in Support of Nonplacebo EEG-NF

Neurofeedback is in vogue. Ideas regarding self-regulation of brain processing have received a great deal of attention in the psychological and neurological sciences (Thibault et al., 2015). Moreover, EEG-nf research is thriving (see Figure 1; Thibault et al., 2015; van Boxtel & Gruzelier, 2014). Expanding from a seminal experiment back in 1958, the field of neurofeedback now boasts two international research societies, two devoted journals, dozens of annual conferences, and hundreds of publications each year that largely endorse EEG-nf and often promote it as a viable clinical tool. Some experiments report objective changes in brain activity after neurofeedback (e.g., Beauregard & Lévesque, 2006; Engelbregt et al., 2016; Ghaziri et al., 2013; Kropotov et al., 2005; Lévesque, Beauregard, & Mensour, 2006; Ros et al., 2013, 2016; Strehl, Leins, et al., 2006; see Appendix A for a discussion on the mechanisms underlying neural regulation) and others highlight a clinical efficacy on par with standard-of-care pharmaceutical treatments (e.g., Flisiak-Antonijczuk, Adamowska, Chładzińska-Kiejna, Kalinowski, & Adamowski, 2015; Fuchs, Birbaumer, Lutzenberger, Gruzelier, & Kaiser, 2003; Kotchoubey et al., 2001; Rossiter & La Vaque, 1995). Meanwhile, few formal ac-




Figure 1. The line representing the number of publications on neurofeedback using electroencephalography has been following a steep ascent in recent time, yet fundamental questions linger concerning specificity and mechanisms of action. The plot shows data from the search query (*EEG OR electroencephalogra**) AND (*neurofeedback OR biofeedback*) in the field “Article Title, Abstract, Keywords” in Scopus. See the online article for the color version of this figure.



Amir Raz

counts document relative shortcomings or take a critical look at EEG-nf (see [Appendix B](#) for a series of informal expert accounts).

Weak evidence supports the efficacy of EEG-nf above and beyond comparable sham treatments; this state-of-affairs prevents the medical community from adding EEG-nf to the clinical standard-of-care armamentarium ([Thibault & Raz, 2016b](#)). For example, only one double-blind, sham-controlled EEG-nf experiment has ever documented clinical superiority of veritable over sham feedback ([Ramos-Murguialday et al., 2013](#)). This highly cited stroke rehabilitation experiment, however, provided over a dozen hour-long physiotherapy sessions between initial and final behavioral measures and further shies away from reporting the raw EEG data supporting a relationship between successful neural modulation and motor improvement.

Whereas all other clinical EEG-nf experiments employing double-blind, sham-controlled designs sought to treat ADHD ([Thibault et al., 2016](#)), a few oft-cited studies leverage alternative control methods and aim to treat refractory epilepsy ([Kotchoubey et al., 2001](#); [Lubar et al., 1981](#); [Serman & MacDonald, 1978](#)). Two seminal experiments alternate between one- ([Lubar et al., 1981](#)) and 3-month-long ([Serman & MacDonald, 1978](#)) training periods wherein researchers first provide positive feedback for increasing a select subset of EEG activity, and then reverse the reward contingency without the explicit knowledge of patients (i.e., display positive feedback for decreasing the same subset of neural activity). Whereas this within-subjects, inverse-sham design holds strong potential to unveil the specificity of EEG-nf, these experiments shied away from analyzing differences in seizure frequency among any of the baseline

measures, veritable training, and inverse-sham neurofeedback. One study reports no statistical analysis ([Lubar et al., 1981](#)) and the other ([Serman & MacDonald, 1978](#)) demonstrates only a reduction in seizure frequency after patients complete both veritable and sham training. These reports oversell the specificity of EEG-nf.

Research efforts that compare placebo factors between EEG-nf and standard treatment are few and far between. For example, one experiment found comparable reductions in seizure frequency, alongside similar levels of self-reported placebo variables (e.g., therapist quality and treatment satisfaction) between patients receiving EEG-nf and those under a new medication regimen; both EEG-nf and medication groups outperformed a respiration biofeedback control condition ([Kotchoubey et al., 2001](#)). This experimental design controlled for the involvement of many placebo factors. The researchers, however, maintained a hypothesis in favor of EEG-nf—potentially exerting greater demand characteristics on neurofeedback participants—and the EEG-nf group trained to improve their condition for 35 sessions of 90 min, rather than the 35 sessions of 10 min employed in respiration biofeedback or the less time-intensive and rather effortless medication condition. Thus, while this study provides substantial evidence for the benefits of EEG-nf, the involvement of placebo influence remains a concern.

Other arguments for the specificity of EEG-nf rest on the assumption that findings from well-controlled biofeedback studies generalize to neurofeedback. This assumption is spurious for several reasons. First, whereas some researchers account for a number of placebo factors (e.g., [Flor & Birbaumer, 1993](#)), the introduction of sham biofeedback often demonstrates equivalence between veridical and placebo biofeedback (e.g., [Andrasik & Holroyd, 1980, 1983](#); [Hunyor et al., 1997](#); [Mullinix, Norton, Hack, & Fishman, 1978](#); [Nicassio, Boylan, & McCabe, 1982](#); [Plotkin & Rice, 1981](#); [Rains & Penzien, 2005](#); [Rains, 2008](#)). Second, even if research confirms the specificity of biofeedback, the discrepancy between well-established relationships (e.g., muscle tension and chronic pain or heart rate variability and anxiety) and our muddled insights linking brain oscillations with psychological functioning, precludes generalization. Similarly, findings from the burgeoning field of fMRI-nf, where participants quickly learn to modulate precise hemodynamic brain signals, remain distinct from EEG-nf research ([Sulzer et al., 2013](#)). Despite the growing enthusiasm surrounding fMRI-nf, at this time only sparse evidence supports its clinical utility or posits a superior treatment benefit compared to EEG-nf ([Birbaumer, Ruiz, & Sitaram, 2013](#)). Thus, arguments purporting the specificity of EEG-nf would occasionally rely on studies, which by design had no a priori intention to examine EEG-nf specificity, and scantily support claims for it.

Relevant experiments investigating disorders beyond ADHD and epilepsy used inadequate experimental designs

that prevented disentangling specific effects (i.e., benefits driven by presenting and attempting to modulate a brain signal of interest) from nonspecific factors (i.e., all other aspects related to undergoing neurofeedback: for example, placebo response, participant expectation, demand characteristics, and spontaneous remission). While this absence of evidence hardly implies evidence of absence, the onus of proof rests on those who advocate for and make claims regarding the specificity of EEG-nf (Thibault & Raz, 2016a). Taken together, while EEG-nf alters both brain and behavior, the necessity of receiving veritable feedback to

derive therapeutic benefits remains largely unconfirmed and rests on rather tenuous foundations (see Table 1 for rebuttals concerning common arguments in favor of EEG-nf and Appendix B for additional insights).

The theoretical underpinnings at the core of EEG-nf seem dubious (Beyerstein, 1990; Kline, Brann, & Loney, 2002). Based on research findings correlating clinical conditions with quantitative differences in electrical brain activity, most neurofeedback protocols aim to increase or decrease a select bandwidth of neural oscillations (Thibault et al., 2015). For example, because high beta activity typically

Table 1
Specificity in Neurofeedback Using Electroencephalography (EEG-nf)

Argument	Research insights and counterarguments challenging EEG-nf
Animals respond to EEG-nf but do not respond to placebos.	The main paper referenced to support this tenuous argument demonstrated that three cats extensively trained with EEG-nf, compared to three untreated cats, expressed delayed seizure onset in response to the injection of an epileptogenic compound (Serman, LoPresti, & Fairchild, 1969). This elderly and methodologically-weak study employed neither statistical analysis nor blinding. Whereas, at least one additional experiment supports the idea that animals can benefit from EEG-nf (Serman, Goodman, & Kovalesky, 1978), this idea has no bearing on whether the relevant effects are placebo based. Indeed, animals do respond to placebos. In a blinded study, researchers found that 28 of 34 epileptic dogs responded to placebo treatment (Munana, Zhang, & Patterson, 2010). Research further documents a range of placebo phenomena in nonhuman animals for a spectrum of objective measures, including antibody production (Ader, Kelly, Moynihan, Grotta, & Cohen, 1993; Jæger, Larsen, & Moe, 2006; McMillan, 1999) and bacterial immunity (Ben-Shaan et al., 2016).
Placebo explanations cannot account for the magnitude of EEG-nf benefits.	Placebos influence many systems including neurotransmitter release, immune responses, hormone levels, cardiopulmonary function, and electrical, hemodynamic, and metabolic brain activity (Price, Finniss, & Benedetti, 2008). Placebo pills improve motor performance in Parkinsonian patients within minutes (Pollo et al., 2002) and sham surgery can benefit patients for years (Moseley et al., 2002). Placebos can lift depression, inhibit pain, and even decrease antibody production in response to allergens (for a review of placebos, see Raz and Harris, 2016). Placebo effects could conceivably drive the benefits of EEG-nf.
EEG-nf treats ADHD equivalent to stimulant medication.	These findings reveal little regarding the mechanisms responsible for neurofeedback-mediated improvement. Only a highly comparable control group (i.e., sham neurofeedback) can reveal whether benefits derive from receiving a particular brain signal. Placebos are not all equal—they wield effects of varying degrees (Kaptchuk et al., 2006). Placebo EEG-nf may prompt greater healing effects than placebo medication. Neurofeedback is more expensive, time consuming, and seemingly cutting edge, and it requires dozens of visits with a practitioner. Thus, comparable results between EEG-nf and a pharmaceutical intervention do not necessarily imply that veritable neurofeedback outperforms sham neurofeedback.
EEG-nf alters objective measures in brain activity.	EEG-nf can alter both electrical (Engelbregt et al., 2016; Kropotov et al., 2005; Strehl, Leins, et al., 2006) and hemodynamic (Beaugard & Lévesque, 2006; Lévesque et al., 2006) brain signals. Ulterior factors, however, including expectation, sitting attentively for multiple sessions, and regularly visiting a practitioner can also drive the observed neurological changes. Attempting to alter a sham neurofeedback signal alone activates various brain regions compared to passively viewing the same sham neurofeedback stream (Ninaus et al., 2013).
Double-blind studies are inappropriate for EEG-nf research.	We have encountered all kinds of arguments along these lines, including that neurofeedback is a behavioral therapy, patients are heterogeneous and need individualized training, sham treatment is unethical, therapists must manually adjust reward thresholds, patient–therapist interactions preclude blinding, and the blind is too easily broken (see, for example, Arns, Heinrich, & Strehl, 2014; Hammond, 2010; Kotchoubey et al., 2001). However, research on behavioral therapies often include placebo controls (e.g., Hofmann & Smits, 2008), cohorts are no more heterogeneous than in other clinical experiments and blinding individualized treatments is feasible, sham treatments represent standard clinical research practice, automatic thresholding remains viable, and blinding is maintainable (Arnold et al., 2013).
Insufficient funding precludes robust experiments with large samples.	Researchers have acquired ample funding to produce thousands of EEG-nf publications and run large-scale experiments (e.g., Gevensleben et al., 2009, $n = 72$; Monastra, Monastra, & George, 2002, $n = 100$; Janssen et al., 2016, $n = 112$; Kaiser & Othmer, 2000, meta-analysis $n = 1,089$). And yet, most EEG-nf experiments scantily employ adequate controls as part of their research design.
The FDA approved neurofeedback.	In 1976, the FDA approved EEG-nf for general relaxation training as a Class II medical device (i.e., one that has insufficient information to provide reasonable assurance of the safety and effectiveness of the device: <i>Medical Device Regulation Act, 1976</i>). The FDA supports no further claims.

Note. ADHD = attention-deficit/hyperactivity disorder; FDA = U.S. Food and Drug Administration. This table challenges a number of seemingly strong arguments purporting that the benefits of EEG-nf rely on the administration of a contingent and precise brain signal.

correlates with heightened attention, many protocols aim to reinforce beta activity in the treatment of ADHD. If beta oscillations paralleled only a few specific cognitive processes, such logic may hold some appeal; however, beta activity correlates with a wide range of behaviors. As a case in point, alcoholics express high baseline beta activity (Rangaswamy et al., 2002); however, one could hardly argue that upregulating beta would induce alcoholism. Research findings also demonstrate that beta oscillations correlate with poor attention in ADHD patients, rather than with heightened attention as observed in children without ADHD (Ogrim, Kropotov, & Hestad, 2012).

These wide-ranging behavioral correlates exist across many common EEG-nf targets. For example, while heightened alpha amplitude correlates with meditation (Lagopoulos et al., 2009), attentional suppression (Foxe & Snyder, 2011), working memory (Jensen, Gelfand, Kounios, & Lisman, 2002), eye closure (Barry, Clarke, Johnstone, Magee, & Rushby, 2007) and anxiety (Klimesch, Sauseng, & Hanslmayr, 2007), EEG-nf participants train to amplify alpha activity to relieve depression (Choi et al., 2010), improve cognitive performance (Hanslmayr, Sauseng, Doppelmayr, Schabus, & Klimesch, 2005), and treat phobias, obsessive-compulsive disorder, posttraumatic stress, and anxiety (Moore, 2000). While some EEG bandwidths have strongly supported behavioral correlates (e.g., delta and deep sleep or gamma and sensory processing: Jensen, Kaiser, & Lachaux, 2007) insufficient data exists to argue that inducing these oscillations would drive the associated behavior. Taken together, these insights highlight the lack of coherence between recorded electrophysiological brain oscillations—signals derived from the interaction of multiple disparate brain processes—and single behaviors.

If EEG-nf were a powerful and focal tool to modulate brain function in relation to specific behaviors, we would expect to see adverse reactions in some participants (Raz & Michels, 2007; Thibault et al., 2016), especially as distinct experiments encourage neural regulation in opposite directions (e.g., Ros et al., 2016, vs. Zoefel, Huster, & Herrmann, 2011). And yet, after almost six decades of neurofeedback research, reports of negative effects remain anecdotal (Hammond & Kirk, 2008). Taken together, therefore, the theory supporting EEG-nf feeds on a prevalent, albeit injudicious, propensity to reduce multifaceted behaviors to single brain processes (McCabe & Castel, 2008; Weisberg, Keil, Goodstein, Rawson, & Gray, 2008).

While a few nonstandard EEG-nf techniques negotiate the aforementioned foundational shortcomings, they come peppered with other caveats and conflicts of interest. For example, z-score neurofeedback aims to alter brain activity in participants to match an averaged signal derived from a database of healthy individuals. This technique overlooks individual variations in physiology and anatomy (e.g., skull thickness), which substantially distort electrical neural sig-

nals. In a bibliography of z-score neurofeedback (Applied Neuroscience Inc., 2014), the first author on 37 of the 39 publications included (i.e., 95%) either runs a private EEG-nf practice or sells neurofeedback equipment. Such conflicts of interest extend to the International Society for Neurofeedback and Research, where eight of nine board members practice privately and the ninth sells EEG-nf products; the journal *NeuroRegulation*, featuring both an editor-in-chief and an executive editor who practice EEG-nf privately; and the Biofeedback Certification International Alliance, Biofeedback Federation of Europe, and Association for Applied and Psychophysiology and Biofeedback, where many members hold active financial stakes in EEG-nf. Notably, financial conflicts of interest also pervade common clinical research (Bekelman & Gross, 2003; Perlis et al., 2005), the expansive pharmaceutical literature (Antonuccio, Danton, & McClanahan, 2003; Rabipour, Delpiero, & Raz, 2011), prevalent brain training programs (Underwood, 2016), and to a lesser but nonnegligible extent, research on psychological therapies (Lieb, Osten-Sacken, Stoffers-Winterling, Reiss, & Barth, 2016). Even in the absence of financial interest, moreover, comparative studies across behavioral treatment, psychotherapy, and pharmacology, tend to skew findings toward the specific choice-of-treatment espoused by the authors (Luborsky et al., 1999; Maj, 2008). Such undesirable biases may also pertain to clinicians who teach or practice a specific technique, especially when monetary transactions loom (e.g., Farah, 2009; Grunbaum, 1986). Such financial investment likely drives publication bias (Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008) and encourages research designs that conflate the benefits of specific mechanism with psychosocial influences, thus inflating the literature with positive findings (Bekelman & Gross, 2003; Perlis et al., 2005).

Placebo Science and Clinical Practice in the Context of EEG-NF

EEG-nf works, but it likely relies heavily on placebo phenomena. Whereas the biomedical lore often discounts placebo effects (Raz & Harris, 2016), most accepted treatments that target brain function and behavior—from psychiatry (Weimer, Colloca, & Enck, 2015) to gastroenterology and the brain-gut axis (Elsenbruch & Enck, 2015)—derive substantial benefits from such psychosocial variables (e.g., see antidepressants in Kirsch, 2009; Kirsch et al., 2008). Particularly, some alternative interventions outperform standard-of-care treatments while relying almost entirely on placebo effects (e.g., see acupuncture in Harris, Lifshitz, & Raz, 2015). Placebo effects extend beyond behavioral measures and impact various physiological systems. Through cleverly designed experiments and the use of molecular imaging techniques, researchers demonstrated that placebo analgesics can alter neurotransmitter release (e.g., endogenous opioids:

Levine, Gordon, & Fields, 1978; ter Riet, De Craen, De Boer, & Kessels, 1998; Zubieta et al., 2005) and fMRI-indexed brain activity (Kong et al., 2006). Sham neurofeedback, moreover, alters activity originating from a host of cortical regions (Ninaus et al., 2013). If further research confirms the effectiveness of neurofeedback relative to accepted treatments (e.g., Flisiak-Antonijczuk et al., 2015; Fuchs et al., 2003; Kotchoubey et al., 2001; Rossiter & La Vaque, 1995), EEG-nf may well triumph as a therapy.

Important variables for therapists to consider when contemplating neurofeedback include the number needed to treat (NNT), number needed to harm (NNH), potential complications arising from forgoing standard care, the sustainability of positive outcomes, and the probability and severity of side effects. These variables provide informative trends concerning some standard therapies. For example, consider the field of child psychiatry (Raz, 2006). On the one hand, pediatric antidepressant treatment carries an NNT between three and 10 (i.e., for every three to 10 children administered antidepressants, only one will improve better than placebo), an NNH (e.g., in terms of suicidal ideation or suicide attempt) from 112 to 200 (Bridge et al., 2007), and a range of potentially severe side effects (Jureidini, Doecke, Mansfield, Haby, & Menkes, 2004); pharmacological treatment of ADHD with atomoxetine carries an NNT of three for treatment response and 10 for relapse prevention, and an NNH of nine for abdominal pain, 22 for vomiting, 30 for dyspepsia, and 19 for somnolence (Cheng, Chen, Ko, & Ng, 2007). On the other hand, EEG-nf studies rarely report NNT or NNH, yet side effects remain mild and uncommon (Hammond & Kirk, 2008), and positive outcomes appear to persist well beyond the treatment period (Gani, Birbaumer, & Strehl, 2008; Gevensleben et al., 2010; Leins et al., 2007; Strehl, Leins, et al., 2006). In a clinical setting, therefore, critically assessing treatment options should reach far beyond significance testing and *p* values, and further rely on quantitative and qualitative evaluations of potential complications, treatment sustainability, and the transferability of effects.

Notably, standard neurofeedback treatment often comprises 40 sessions and costs between \$4,000 and \$10,000 USD (Thibault et al., 2015). If researchers can isolate the underlying placebo mechanisms, practitioners may afford the opportunity to forgo expensive and lengthy training regimes while continuing to offer an effective nonpharmaceutical alternative. For example, if interacting with patients prompts positive outcomes, practitioners could spend more time communicating before commencing neurofeedback. A new wave of research aimed at unveiling psychosocial factors could encourage practitioners to leverage and amplify these therapeutic effects.

Whereas current EEG-nf studies largely neglect investigating treatment mechanisms that rely on participant motivation, belief in the treatment administered, interacting with a practitioner, level of positive feedback, and sense of

control of their brain signal, future experimental designs could aim to isolate and modulate these factors to better identify their relative contributions in neurofeedback-mediated healing (Thibault et al., 2016). Increasingly, EEG-nf experiments administer sham neurofeedback to control for psychosocial variables. These study designs can unveil the importance (or lack thereof) of veritable feedback, but fall short from teasing apart the nonspecific elements that drive healing. Rather than maintaining all psychosocial variables fixed, while altering only veritable and sham feedback, novel research designs could aim to enhance and inhibit individual placebo variables to establish their involvement in EEG-nf and propel a more scientific understanding of neurofeedback (e.g., Rains, 2008).

Conclusion

Placebo effects dominate EEG-nf outcomes. Whereas most neurofeedback experts acquiesce to this insight, researchers and practitioners largely shy away from openly disclosing, let alone formally reporting, the involvement and magnitude of these psychosocial factors. In light of the comparable benefits of veritable-versus-sham feedback, conflicts of interest, and a weak theoretical underpinning, advocating for EEG-nf poses a conundrum. On the one hand, many patients erroneously assume they have “nothing to lose” (Raz & Harris, 2016). On the other hand, EEG-nf entails a degree of deception—the putative mechanisms differ from the actual underlying mechanisms. Moreover, cheaper and less time-intensive options may be available.

Neurofeedback remains a viable treatment of choice for patients with sufficient time, money, and motivation to pursue it. Despite and perhaps because the insight that placebos play such a central role in EEG-nf outcomes, researchers and practitioners would stand to benefit from diverting their efforts away from a tireless search for elusive neurological underpinnings and focus instead on dissecting these overarching influences. If researchers propose to unravel the psychology of neurofeedback, and proponents remain transparent about the underlying mechanisms, we believe practitioners can apply EEG-nf in a manner fitting with standard biomedical ethics.

References

- Ader, R., Kelly, K., Moynihan, J. A., Grota, L. J., & Cohen, N. (1993). Conditioned enhancement of antibody production using antigen. *Brain, Behavior, and Immunity*, 7, 334–343.
- Andrasik, F., & Holroyd, K. A. (1980). A test of specific and nonspecific effects in the biofeedback treatment of tension headache. *Journal of Consulting and Clinical Psychology*, 48, 575–586.
- Andrasik, F., & Holroyd, K. A. (1983). Specific and nonspecific effects in the biofeedback treatment of tension headache: 3-year follow-up. *Journal of Consulting and Clinical Psychology*, 51, 634–636.
- Antonuccio, D. O., Danton, W. G., & McClanahan, T. M. (2003). Psychology in the prescription era: Building a firewall between marketing and science. *The American Psychologist*, 58, 1028–1043.

- Applied Neuroscience Inc. (2014). *Z Score Neurofeedback Publications*. Retrieved December 14, from http://www.appliedneuroscience.com/Z_Score_publications.pdf
- Arnold, L. E., Lofthouse, N., Hersch, S., Pan, X., Hurt, E., Bates, B., . . . Grantier, C. (2013). EEG neurofeedback for ADHD: Double-blind sham-controlled randomized pilot feasibility trial. *Journal of Attention Disorders, 17*, 410–419.
- Arns, M., Heinrich, H., & Strehl, U. (2014). Evaluation of neurofeedback in ADHD: The long and winding road. *Biological Psychology, 95*, 108–115.
- Barry, R. J., Clarke, A. R., Johnstone, S. J., Magee, C. A., & Rushby, J. A. (2007). EEG differences between eyes-closed and eyes-open resting conditions. *Clinical Neurophysiology, 118*, 2765–2773.
- Beaugard, M., & Lévesque, J. (2006). Functional magnetic resonance imaging investigation of the effects of neurofeedback training on the neural bases of selective attention and response inhibition in children with attention-deficit/hyperactivity disorder. *Applied Psychophysiology and Biofeedback, 31*, 3–20.
- Bekelman, J. E., & Gross, C. P. (2003). Scope and impact of financial conflicts of interest in biomedical research. *Journal of the American Medical Association, 289*, 454–465.
- Ben-Shaanan, T. L., Azulay-Debby, H., Dubovik, T., Starosvetsky, E., Korin, B., Schiller, M., . . . Rolls, A. (2016). Activation of the reward system boosts innate and adaptive immunity. *Nature Medicine, 22*, 940–944.
- Beyerstein, B. L. (1990). Brainscams: Neuromythologies of the New Age. *International Journal of Mental Health Systems, 19*, 27–36.
- Birbaumer, N., Ruiz, S., & Sitaram, R. (2013). Learned regulation of brain metabolism. *Trends in Cognitive Sciences, 17*, 295–302.
- Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., . . . Brent, D. A. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. *Journal of the American Medical Association, 297*, 1683–1696.
- Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. *Psychopharmacology, 194*, 197–209.
- Choi, S. W., Chi, S. E., Chung, S. Y., Kim, J. W., Ahn, C. Y., & Kim, H. T. (2010). Is alpha wave neurofeedback effective with randomized clinical trials in depression? A pilot study. *Neuropsychobiology, 63*, 43–51.
- Elsenbruch, S., & Enck, P. (2015). Placebo effects and their determinants in gastrointestinal disorders. *Nature Reviews Gastroenterology & Hepatology, 21*, 472–485.
- Engelbregt, H. J., Keeser, D., van Eijk, L., Suiker, E. M., Eichhorn, D., Karch, S., . . . Pogarell, O. (2016). Short and long-term effects of sham-controlled prefrontal EEG-neurofeedback training in healthy subjects. *Clinical Neurophysiology, 127*, 1931–1937.
- Esmail, S., & Linden, D. (2014). Neural networks and neurofeedback in Parkinson's disease. *NeuroRegulation, 1*, 240–272.
- Farah, M. J. (2009). A picture is worth a thousand dollars. *Journal of Cognitive Neuroscience, 21*, 623–624.
- Flisiak-Antonijczuk, H., Adamowska, S., Chłodzińska-Kiejna, S., Kalinowski, R., & Adamowski, T. (2015). Evaluation of the efficacy of ADHD treatment with the use of EEG-biofeedback method in comparison to methylphenidate. *Archives of Psychiatry and Psychotherapy, 17*, 32–38.
- Flor, H., & Birbaumer, N. (1993). Comparison of the efficacy of electromyographic biofeedback, cognitive-behavioral therapy, and conservative medical interventions in the treatment of chronic musculoskeletal pain. *Journal of Consulting and Clinical Psychology, 61*, 653–658.
- Foxe, J. J., & Snyder, A. C. (2011). The role of alpha-band brain oscillations as a sensory suppression mechanism during selective attention. *Frontiers in Psychology, 2*, 1–13.
- Fuchs, T., Birbaumer, N., Lutzenberger, W., Gruzelier, J. H., & Kaiser, J. (2003). Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: A comparison with methylphenidate. *Applied Psychophysiology and Biofeedback, 28*, 1–12.
- Gani, C., Birbaumer, N., & Strehl, U. (2008). Long term effects after feedback of slow cortical potentials and of theta-beta-amplitudes in children with attention-deficit/hyperactivity disorder (ADHD). *International Journal of Bioelectromagnetism, 10*, 209–232.
- Gevensleben, H., Holl, B., Albrecht, B., Schlamp, D., Kratz, O., Studer, P., . . . Heinrich, H. (2009). Distinct EEG effects related to neurofeedback training in children with ADHD: A randomized controlled trial. *International Journal of Psychophysiology, 74*, 149–157.
- Gevensleben, H., Holl, B., Albrecht, B., Schlamp, D., Kratz, O., Studer, P., . . . Heinrich, H. (2010). Neurofeedback training in children with ADHD: 6-month follow-up of a randomised controlled trial. *European Child & Adolescent Psychiatry, 19*, 715–724.
- Ghaziri, J., Tucholka, A., Larue, V., Blanchette-Sylvestre, M., Reyburn, G., Gilbert, G., . . . Beauregard, M. (2013). Neurofeedback training induces changes in white and gray matter. *Clinical EEG and Neuroscience, 44*, 265–272.
- Grunbaum, A. (1986). Precis of the foundations of psychoanalysis: A philosophical critique. *Behavioral & Brain Sciences, 9*, 217–228.
- Gruzelier, J. H. (2014). EEG-neurofeedback for optimising performance. III: A review of methodological and theoretical considerations. *Neuroscience and Biobehavioral Reviews, 44*, 159–182.
- Hammond, D. C. (2010). The need for individualization in neurofeedback: Heterogeneity in QEEG patterns associated with diagnoses and symptoms. *Applied Psychophysiology Biofeedback, 35*, 31–36.
- Hammond, D. C., & Kirk, L. (2008). First, do no harm: Adverse effects and the need for practice standards in neurofeedback. *Journal of Neurotherapy, 12*, 79–88.
- Hanslmayr, S., Sauseng, P., Doppelmayr, M., Schabus, M., & Klimesch, W. (2005). Increasing individual upper alpha power by neurofeedback improves cognitive performance in human subjects. *Applied Psychophysiology and Biofeedback, 30*, 1–10.
- Harris, C. S., Lifshitz, M., & Raz, A. (2015). Acupuncture for chronic pain? Clinical wisdom undecided despite over 4000 years of practice. *The American Journal of Medicine, 128*, 331–333.
- Hofmann, S. G., & Smits, J. A. J. (2008). Cognitive-behavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. *The Journal of Clinical Psychiatry, 69*, 621–632.
- Hunyor, S. N., Henderson, R. J., Lal, S. K. L., Carter, N. L., Kobler, H., Jones, M., . . . Mihailidou, A. S. (1997). Placebo-controlled biofeedback blood pressure effect in hypertensive humans. *Hypertension, 29*, 1225–1231.
- Jæger, G. T., Larsen, S., & Moe, L. (2006). Stratification, blinding and placebo effect in a clinical trial of gold bead implantation in canine hip dysplasia. *European Journal of Companion Animal Practice, 16*, 171–178.
- Janssen, T. W. P., Bink, M., Geladé, K., van Mourik, R., Maras, A., & Oosterlaan, J. (2016). A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD. *Journal of Child Psychology and Psychiatry, 57*, 633–644.
- Jensen, O., Gelfand, J., Kounios, J., & Lisman, J. E. (2002). Oscillations in the alpha band (9–12 Hz) increase with memory load during retention in a short-term memory task. *Cerebral Cortex, 12*, 877–882.
- Jensen, O., Kaiser, J., & Lachaux, J.-P. (2007). Human gamma-frequency oscillations associated with attention and memory. *Trends in Neurosciences, 30*, 317–324.
- Jureidini, J. N., Doecke, C. J., Mansfield, P. R., Haby, M. M., & Menkes, D. B. (2004). Clinical review efficacy and safety of antidepressants for children and adolescents. *British Medical Journal, 328*, 879–883.

- Kaiser, D. A., & Othmer, S. (2000). Effect of neurofeedback on variables of attention in a large multi-center trial. *Journal of Neurotherapy*, 4, 5–15.
- Kaptchuk, T. J., Stason, W. B., Davis, R. B., Legedza, A. R. T., Schnyer, R. N., Kerr, C. E., . . . Goldman, R. H. (2006). Sham device v inert pill: Randomised controlled trial of two placebo treatments. *British Medical Journal*, 332, 391–397. <http://dx.doi.org/10.1136/bmj.38726.603310.55>
- Kirsch, I. (2009). *The emperor's new drugs: Exploding the antidepressant myth*. London, United Kingdom: The Bodley Head.
- Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. *PLoS Medicine*, 5, 0260–0268.
- Klimesch, W., Sauseng, P., & Hanslmayr, S. (2007). EEG alpha oscillations: The inhibition-timing hypothesis. *Brain Research Reviews*, 53, 63–88.
- Kline, J. P., Brann, C. N., & Loney, B. R. (2002). A cacophony in the brainwaves: A critical appraisal of neurotherapy for attention-deficit disorders. *The Scientific Review of Mental Health Practice: Objective Investigations of Controversial and Unorthodox Claims in Clinical Psychology, Psychiatry, and Social Work*, 1, 44–54.
- Kong, J., Gollub, R. L., Rosman, I. S., Webb, J. M., Vangel, M. G., Kirsch, I., & Kaptchuk, T. J. (2006). Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. *Journal of Neuroscience*, 26, 381–388.
- Koralek, A. C., Jin, X., Long, J. D., Costa, R. M., & Carmena, J. M. (2012). Corticostriatal plasticity is necessary for learning intentional neuroprosthetic skills. *Nature*, 483, 331–335.
- Kotchoubey, B., Strehl, U., Uhlmann, C., Holzapfel, S., König, M., Fröscher, W., . . . Birbaumer, N. (2001). Modification of slow cortical potentials in patients with refractory epilepsy: A controlled outcome study. *Epilepsia*, 42, 406–416.
- Kropotov, J. D., Grin-Yatsenko, V. A., Ponomarev, V. A., Chutko, L. S., Yakovenko, E. A., & Nikishina, I. S. (2005). ERPs correlates of EEG relative beta training in ADHD children. *International Journal of Psychophysiology*, 55, 23–34.
- Lagopoulos, J., Xu, J., Rasmussen, I., Vik, A., Malhi, G. S., Eliassen, C. F., . . . Ellingsen, O. (2009). Increased theta and alpha EEG activity during nondirective meditation. *Journal of Alternative and Complementary Medicine*, 15, 1187–1192.
- Lansbergen, M. M., van Dongen-Boomsma, M., Buitelaar, J. K., & Slaats-Willemse, D. (2011). ADHD and EEG-neurofeedback: A double-blind randomized placebo-controlled feasibility study. *Journal of Neural Transmission*, 118, 275–284.
- Leins, U., Goth, G., Hinterberger, T., Klinger, C., Rumpf, N., & Strehl, U. (2007). Neurofeedback for children with ADHD: A comparison of SCP and theta/beta protocols. *Applied Psychophysiology and Biofeedback*, 32, 73–88.
- Lévesque, J., Beauregard, M., & Mensour, B. (2006). neurofeedback training on the neural substrates of selective attention in children with attention-deficit/hyperactivity disorder: A functional magnetic resonance imaging. *Neuroscience Letters*, 301, 45–48.
- Levine, J. D., Gordon, N. C., & Fields, H. L. (1978). The mechanism of placebo analgesia. *The Lancet*, 312, 654–657.
- Lieb, K., Osten-Sacken, J. von der, Stoffers-Winterling, J., Reiss, N., & Barth, J. (2016). Conflicts of interest and spin in reviews of psychological therapies: A systematic review. *British Medical Journal*, 6, e010606.
- Lofthouse, N., Arnold, L. E., Hersch, S., Hurt, E., & DeBeus, R. (2012). A review of neurofeedback treatment for pediatric ADHD. *Journal of Attention Disorders*, 16, 351–372.
- Logeman, H. N. A., Lansbergen, M. M., van Os, T. W. D. P., Bocker, K. B. E., & Kenemans, J. L. (2010). The effectiveness of EEG-feedback on attention, impulsivity and EEG: A sham feedback controlled study. *Neuroscience Letters*, 479, 49–53.
- Lubar, J. F., Shabsin, H. S., Natelson, S. E., Holder, G. S., Whitsett, S. F., Pamplin, W. E., & Krulikowski, D. I. (1981). EEG operant conditioning in intractable epileptics. *Archives of Neurology*, 38, 700–704.
- Luborsky, L., Diguier, L., Seligman, D. A., Rosenthal, R., Krause, E. D., Johnson, S., . . . Schweizer, E. (1999). The researcher's own therapy allegiances: A "wild card" in comparisons of treatment efficacy. *Clinical Psychology: Science and Practice*, 6, 95–106.
- Maj, M. (2008). Non-financial conflicts of interests in psychiatric research and practice. *British Journal of Psychiatry*, 193, 91–92.
- McCabe, D. P., & Castel, A. D. (2008). Seeing is believing: The effect of brain images on judgments of scientific reasoning. *Cognition*, 107, 343–352.
- McMillan, F. D. (1999). The placebo effect in animals. *Journal of the American Veterinary Medical Association*, 215, 992–999.
- Medical Device Regulation Act, 94th U.S.C. (1976). Retrieved from <https://www.gpo.gov/fdsys/pkg/STATUTE-90/pdf/STATUTE-90-Pg539.pdf>
- Monastra, V. J., Monastra, D. M., & George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. *Applied Psychophysiology and Biofeedback*, 27, 231–249.
- Moore, N. C. (2000). A review of EEG biofeedback treatment of anxiety disorders. *Clinical EEG and Neuroscience*, 31, 1–6.
- Moseley, J. B., O'Malley, K., Petersen, N. J., Menke, T. J., Brody, B. A., Kuykendall, D. H., . . . Wray, N. P. (2002). A controlled trial of arthroscopic surgery for osteoarthritis of the knee. *The New England Journal of Medicine*, 347, 81–88.
- Mullinix, J. M., Norton, B. J., Hack, S., & Fishman, M. A. (1978). Skin temperature biofeedback and migraine. *Headache*, 17, 242–244.
- Munana, K. R., Zhang, D., & Patterson, E. E. (2010). Placebo effect in canine epilepsy trials. *Journal of Veterinary Internal Medicine*, 24, 166–170.
- Nicassio, P. M., Boylan, M. B., & McCabe, T. G. (1982). Progressive relaxation, EMG biofeedback and biofeedback placebo in the treatment of sleep-onset insomnia. *The British Journal of Medical Psychology*, 55, 159–166.
- Ninaus, M., Kober, S. E., Witte, M., Koschutnig, K., Stangl, M., Neuper, C., & Wood, G. (2013). Neural substrates of cognitive control under the belief of getting neurofeedback training. *Frontiers in Human Neuroscience*, 7, 914.
- Ogrim, G., Kropotov, J., & Hestad, K. (2012). The quantitative EEG theta/beta ratio in attention deficit/hyperactivity disorder and normal controls: Sensitivity, specificity, and behavioral correlates. *Psychiatry Research*, 198, 482–488.
- Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005). Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. *American Journal of Psychiatry*, 162, 1957–1960.
- Perreau-Linck, E., Lessard, N., Lévesque, J., & Beauregard, M. (2010). Effects of neurofeedback training on inhibitory capacities in ADHD children: A single-blind, randomized, placebo-controlled study. *Journal of Neurotherapy*, 14, 229–242.
- Plotkin, W. P., & Rice, K. M. (1981). Biofeedback as a placebo: Anxiety reduction facilitated by training in either suppression or enhancement of alpha brainwaves. *Journal of Consulting and Clinical Psychology*, 49, 590–596.
- Pollo, A., Torre, E., Lopiano, L., Rizzone, M., Lanotte, M., Cavanna, A., . . . Benedetti, F. (2002). Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. *Neuroreport*, 13, 1383–1386.
- Price, D. D., Finniss, D. G., & Benedetti, F. (2008). A comprehensive review of the placebo effect: Recent advances and current thought. *Annual Review of Psychology*, 59, 565–590.
- Rabipour, S., Delpero, E., & Raz, A. (2011). Quandaries and perspectives on potential bias. *AJOB Neuroscience*, 2, 35–37.

- Rains, J. C. (2008). Change mechanisms in EMG biofeedback training: Cognitive changes underlying improvements in tension headache. *Headache*, *48*, 735–736.
- Rains, J. C., & Penzien, D. B. (2005). Behavioral research and the double-blind placebo-controlled methodology. *Headache*, *45*, 479–486.
- Ramos-Murguialday, A., Broetz, D., Rea, M., Laer, L., Yilmaz, O., Brasil, F. L., . . . Birbaumer, N. (2013). Brain-machine interface in chronic stroke rehabilitation: A controlled study. *Annals of Neurology*, *74*, 100–108.
- Rangaswamy, M., Porjesz, B., Chorlian, D. B., Wang, K., Jones, K. A., Bauer, L. O., . . . Begleiter, H. (2002). Beta power in the EEG of alcoholics. *Biological Psychiatry*, *52*, 831–842.
- Raz, A. (2006). Perspectives on the efficacy of antidepressants for child and adolescent depression. *PLoS Medicine*, *3*, 35–41.
- Raz, A., & Harris, C. (Eds.). (2016). *Placebo talks: Modern perspectives on placebos in society*. New York, NY: Oxford University Press.
- Raz, A., & Michels, R. (2007). Contextualizing specificity: Specific and non-specific effects of treatment. *American Journal of Clinical Hypnosis*, *50*, 177–182.
- Ros, T., Frewen, P., Theberge, J., Michela, A., Kluetsch, R., Mueller, A., . . . Lanius, R. A. (2016). Neurofeedback tunes scale-free dynamics in spontaneous brain activity. *Cerebral Cortex*. Advance online publication. <http://dx.doi.org/10.1093/cercor/bhw285>
- Ros, T., Theberge, J., Frewen, P. A., Kluetsch, R., Densmore, M., Calhoun, V. D., & Lanius, R. A. (2013). Mind over chatter: Plastic up-regulation of the fMRI salience network directly after EEG neurofeedback. *NeuroImage*, *65*, 324–335.
- Rossiter, D. T. R., & La Vaque, T. J. (1995). A comparison of EEG biofeedback and psychostimulants in treating attention deficit/hyperactivity disorders. *Journal of Neurotherapy*, *1*, 48–59.
- Soekadar, S. R., Witkowski, M., Birbaumer, N., & Cohen, L. G. (2015). Enhancing Hebbian learning to control brain oscillatory activity. *Cerebral Cortex*, *25*, 2409–2415.
- Soekadar, S. R., Witkowski, M., Cossio, E. G., Birbaumer, N., Robinson, S. E., & Cohen, L. G. (2013). In vivo assessment of human brain oscillations during application of transcranial electric currents. *Nature Communications*, *4*, 2032.
- Sonuga-Barke, E. J. S., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., . . . Sergeant, J. (2013). Nonpharmacological interventions for ADHD: Systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. *The American Journal of Psychiatry*, *170*, 275–289.
- Serman, M. B., Goodman, S. J., & Kovalsky, R. A. (1978). Effects of sensorimotor EEG feedback training on seizure susceptibility in the rhesus monkey. *Experimental Neurology*, *62*, 735–747.
- Serman, M. B., LoPresti, R. W., & Fairchild, M. D. (1969). *Electroencephalographic and behavioral studies of monomethylhydrazine toxicity in the cat*. Wright-Patterson Air Force Base, OH: Aerospace Medical Research Laboratory.
- Serman, M. B., & MacDonald, L. (1978). Effects of central cortical EEG feedback training on incidence of poorly controlled seizures. *Epilepsia*, *19*, 207–222.
- Strehl, U., Leins, U., Goth, G., Klinger, C., Hinterberger, T., & Birbaumer, N. (2006). Self-regulation of slow cortical potentials: A new treatment for children with attention-deficit/hyperactivity disorder. *Pediatrics*, *118*, e1530–e1540.
- Strehl, U., Trevorrow, T., Veit, R., Hinterberger, T., Kotchoubey, B., Erb, M., & Birbaumer, N. (2006). Deactivation of brain areas during self-regulation of slow cortical potentials in seizure patients. *Applied Psychophysiology and Biofeedback*, *31*, 85–94.
- Sulzer, J., Haller, S., Scharnowski, F., Weiskopf, N., Birbaumer, N., Blefari, M. L., . . . Sitaram, R. (2013). Real-time fMRI neurofeedback: Progress and challenges. *NeuroImage*, *76*, 386–399.
- ter Riet, G., De Craen, A. J. M., De Boer, A., & Kessels, A. G. H. (1998). Is placebo analgesia mediated by endogenous opioids? A systematic review. *Pain*, *76*, 273–275.
- Thibault, R. T., Lifshitz, M., Birbaumer, N., & Raz, A. (2015). Neurofeedback, self-regulation, and brain imaging: Clinical science and fad in the service of mental disorders. *Psychotherapy and Psychosomatics*, *84*, 193–207.
- Thibault, R. T., Lifshitz, M., & Raz, A. (2016). The self-regulating brain and neurofeedback: Experimental science and clinical vogue. *Cortex*, *74*, 247–261.
- Thibault, R. T., & Raz, A. (2016a). Neurofeedback: The power of psychosocial therapeutics. *The Lancet Psychiatry*, *3*, e318.
- Thibault, R. T., & Raz, A. (2016b). When can neurofeedback join the clinical armamentarium? *The Lancet Psychiatry*, *3*, 497–498.
- Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials. *The New England Journal of Medicine*, *358*, 2181–2182.
- Underwood, E. (2016). Regulators seek to tame brain training’s “Wild West.” *Science*, *351*, 212–213.
- van Boxtel, G. J. M., & Gruzelier, J. H. (2014). Neurofeedback: Introduction to the special issue. *Biological Psychology*, *95*, 1–3.
- Van Dongen-Boomsma, M., Vollebregt, M. A., Slaats-Willemse, D., & Buitelaar, J. K. (2013). A randomized placebo-controlled trial of electroencephalographic (EEG) neurofeedback in children with attention-deficit/hyperactivity disorder. *Journal of Clinical Psychiatry*, *74*, 821–827.
- Vollebregt, M. A., van Dongen-Boomsma, M., Buitelaar, J. K., & Slaats-Willemse, D. (2014). Does EEG-neurofeedback improve neurocognitive functioning in children with attention-deficit/hyperactivity disorder? A systematic review and a double-blind placebo-controlled study. *Journal of Child Psychology and Psychiatry, and Allied Disciplines*, *55*, 460–472.
- Vollebregt, M. A., van Dongen-Boomsma, M., Slaats-Willemse, D., & Buitelaar, J. K. (2014). What future research should bring to help resolving the debate about the efficacy of EEG-neurofeedback in children with ADHD. *Frontiers in Human Neuroscience*, *8*, 321.
- Weimer, K., Colloca, L., & Enck, P. (2015). Placebo effects in psychiatry: Mediators and moderators. *The Lancet Psychiatry*, *2*, 246–257.
- Weisberg, D. S., Keil, F. C., Goodstein, J., Rawson, E., & Gray, J. R. (2008). The seductive allure of neuroscience explanations. *Journal of Cognitive Neuroscience*, *20*, 470–477.
- Zoefel, B., Huster, R. J., & Herrmann, C. S. (2011). Neurofeedback training of the upper alpha frequency band in EEG improves cognitive performance. *NeuroImage*, *54*, 1427–1431.
- Zuberer, A., Brandeis, D., & Drechsler, R. (2015). Are treatment effects of neurofeedback training in children with ADHD related to the successful regulation of brain activity? A review on the learning of regulation of brain activity and a contribution to the discussion on specificity. *Frontiers in Human Neuroscience*, *9*, 1–15.
- Zubieta, J.-K., Bueller, J. A., Jackson, L. R., Scott, D. J., Xu, Y., Koeppe, R. A., . . . Stohler, C. S. (2005). Placebo effects mediated by endogenous opioid activity on μ -opioid receptors. *The Journal of Neuroscience*, *25*, 7754–7762.

(Appendices follow)

Appendix A

Mechanism Underlying Learned Neural Regulation

Animal research suggests that intentional and goal-directed operant conditioning drives neurofeedback learning and requires corticostriatal plasticity (Koralek, Jin, Long, Costa, & Carmena, 2012). Whereas neurofeedback studies in nonhuman animals implant electrodes directly into the brain and show clear learning effects, experiments with humans rely on scalp electrodes and only occasionally measure whether participants learn to modulate the signal of interest (e.g., Engelbregt et al., 2016; Strehl, Trevorrow, et al., 2006). Instead, these studies often focus on behavioral variables and other neural measures. Thus, not only does the link between learned neural regulation and behavior remain unclear, sparse evidence supports the idea

that humans can reliably modulate EEG-nf signals. To develop a more scientific basis for EEG-nf, it would behoove researchers to test correlations among learned brain regulation, behavioral measures, and other neural variables. To further shed light on the neural conditions that foster learned regulation, researchers recently developed a technological innovation that allows experimenters to record brain oscillations while applying transcranial DC stimulation to disrupt or enhance specific neural activity (Soekadar et al., 2013; Soekadar, Witkowski, Birbaumer, & Cohen, 2015). Tools of this ilk, combined with increasingly rigorous experimental design hold the key to unveiling the functional role of neural oscillations.

Appendix B

Canvassing the Opinions of Neurofeedback Experts

Visiting an EEG-nf clinic appears on par with the experience of attending a private health center: framed degrees line the walls and the environment mimics that of a medical practice. In a recent visit to a neurofeedback center, we interviewed the lead practitioner who, after two hours of discussion, confided that even he remained unconvinced that presenting a particular brain signal was essential for EEG-nf treatment. Instead, he argued for a comprehensive approach involving multiple concurrent therapies.

Informal discussions with leaders in the field reveal a similar tenor. For example, one of the pioneers of neurofeedback and a leading researcher in the field communicated that it would be naïve to believe that neurofeedback offers an adequate and sufficient treatment for any disorder (Joel Lubar, personal communication, 2016). In line with this opinion, a recent authoritative review states that “it would be foolish to conclude that a foundation of knowledge has been realized enabling textbooks to be written [on EEG-nf]” (Gruzelier, 2014, p. 178). Furthermore, arguably one of the most rigorous and prolific neurofeedback researchers, Niels

Birbaumer, proposed that the cumulative evidence in favor of EEG-nf is preliminary and we stand to benefit from more controlled evidence to confirm that genuine feedback is a necessary component to achieve positive treatment outcomes (personal communication, 2016).

In addition, we recently met with a representative of a nonprofit international neurofeedback organization, who emphasized the omnipresence of business interests and scoffed at the idea that the International Society for Neurofeedback and Research consists of academic researchers. Thus, whereas the published literature may paint a semirigorous and scholarly image of EEG-nf, under this superficial veneer flourish strong business agendas largely incongruent with the standards of academic investigation and medical research.

Received May 10, 2016

Revision received October 16, 2016

Accepted October 22, 2016 ■